TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Mersana Therapeutics ( (MRSN) ).
On November 12, 2025, Mersana Therapeutics entered into a merger agreement with Day One Biopharmaceuticals, under which Day One will acquire Mersana through a tender offer followed by a merger. The deal offers $25.00 per share in cash, plus contingent value rights (CVRs) potentially worth up to $30.25 per share, totaling a deal value of approximately $285 million. The merger, unanimously approved by Mersana’s board, is expected to close by January 2026, subject to customary conditions. This acquisition highlights the potential value of Mersana’s ADCs, particularly the B7-H4-directed Dolasynthen ADC, Emi-Le, and aims to support its development for treating adenoid cystic carcinoma.
The most recent analyst rating on (MRSN) stock is a Hold with a $8.00 price target. To see the full list of analyst forecasts on Mersana Therapeutics stock, see the MRSN Stock Forecast page.
Spark’s Take on MRSN Stock
According to Spark, TipRanks’ AI Analyst, MRSN is a Neutral.
Mersana Therapeutics’ overall stock score is primarily impacted by its challenging financial performance, with ongoing losses and high leverage posing significant risks. Technical analysis and valuation also reflect a cautious outlook, with mixed signals and limited valuation appeal. The earnings call provided some positive clinical progress, but financial challenges remain a concern.
To see Spark’s full report on MRSN stock, click here.
More about Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel antibody-drug conjugates (ADCs) targeting cancers with high unmet medical needs. The company has developed proprietary ADC platforms, including Dolasynthen and Immunosynthen, which have generated a pipeline of product candidates aimed at treating various cancers.
Average Trading Volume: 61,438
Technical Sentiment Signal: Sell
Current Market Cap: $44.27M
Find detailed analytics on MRSN stock on TipRanks’ Stock Analysis page.